May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
The Systemic and Intraocular Levels of Bevacizumab After Topical Administration
Author Affiliations & Notes
  • T. J. Parisi
    Ophthalmology, Mayo Clinic, Rochester, Minnesota
  • S. J. Bakri
    Ophthalmology, Mayo Clinic, Rochester, Minnesota
  • J. S. Pulido
    Ophthalmology, Mayo Clinic, Rochester, Minnesota
  • J. Martinez de Arangon Lancha
    Ophthalmology, Mayo Clinic, Rochester, Minnesota
  • K. H. Baratz
    Ophthalmology, Mayo Clinic, Rochester, Minnesota
  • J. L. Güell
    Ophthalmology, Mayo Clinic, Rochester, Minnesota
  • M. R. Snyder
    Ophthalmology, Mayo Clinic, Rochester, Minnesota
  • R. J. Singh
    Ophthalmology, Mayo Clinic, Rochester, Minnesota
  • Footnotes
    Commercial Relationships T.J. Parisi, None; S.J. Bakri, None; J.S. Pulido, None; J. Martinez de Arangon Lancha, None; K.H. Baratz, None; J.L. Güell, None; M.R. Snyder, None; R.J. Singh, None.
  • Footnotes
    Support Research to Prevent Blindness, Inc., NY, NY and the Mayo Foundation, Rochester, MN.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1704. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. J. Parisi, S. J. Bakri, J. S. Pulido, J. Martinez de Arangon Lancha, K. H. Baratz, J. L. Güell, M. R. Snyder, R. J. Singh; The Systemic and Intraocular Levels of Bevacizumab After Topical Administration. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1704. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Bevacizumab is an anti-VEGF agent used to treat ocular neovascularization. The purpose of this study is to investigate whether topical administration of bevacizumab penetrates the anterior chamber in rabbits.

Methods:: The right eyes of 12 dutch-belted rabbits were treated with topical Bevacizumab 4 times daily after applying a drop of topical proparacaine. Three rabbits were euthanized after 3, 6, and 9 days of topical administration. The medication was discontinued after 9 days of therapy, and the remaining 3 rabbits were sacrificed at day 12 to allow for a washout period. Immediately after euthanization, a blood sample was collected. Paracentesis was performed on all right and left eyes, with withdrawal of 0.1 ml of aqueous humor. The eyes were then enucleated and rapidly frozen in liquid nitrogen for later dissection of the vitreous gel. An immunoassay was performed to measure bevacizumab levels.

Results:: Bevacizumab was detected in the anterior chambers of the treated eyes when administered topically 4 times daily. Bevacizumab levels of treated eyes were significantly higher (48.95 ± 28.40 mg/ml) when compared to the untreated eyes (8.02 ± 8.31 mg/ml). Analysis of vitreous and serum levels is being performed.

Conclusions:: Topical bevacizumab penetrates the anterior chamber.

Keywords: neovascularization • anterior chamber • cornea: basic science 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×